Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences:

• A fireside chat at the Evercore ISI HealthCONx Conference at 12:35 p.m. ET / 9:35 a.m. PT on November 29, 2022; and
• A fireside chat at the JMP Securities Hematology and Oncology Summit at 12:20 p.m. ET / 9:20 a.m. PT on December 7, 2022.

Audio webcasts of both fireside chats will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) in patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia. Tipifarnib, a potent, selective and orally bioavailable FTI, has received Breakthrough Therapy Designation for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC). Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company has also initiated a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in EGFR-mutant non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at www.kuraoncology.com.

Contacts

Company:Pete De SpainSenior Vice President, Investor Relations &Corporate Communications(858) 500-8803[email protected]

Investors:Robert H. UhlManaging DirectorICR Westwicke (858) 356-5932[email protected]

Media:Jason SparkManaging DirectorEvoke Canale(619) 849-6005[email protected]

You May Also Be Interested In

• Skipio Acquires RapidTalk to Expand AI-Powered Customer Engagement
• SecondSideMedia Launches Digital Platform to Address Inaccurate and Misleading AI-Generated Information
• MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration